profit from every $100 of sales.
$0$100
PRF Technologies
$0.78-0.53% today
-83.2% in 1 year
1-year low $0.711-year high $5.65
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What PRF Technologies sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $17,000 in 2025, with -$5.02 million of profit last year.
SalesProfit
PRF Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| PRF Technologies | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads PRF Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | 0 | 0 | -0 | |
| -9 | -10 | -15 | -5 | |
| -9 | -10 | -15 | -4 | |
| -9 | -9 | -15 | -5 | |
| -317.30 | -122.94 | -105.52 | – | |
| – | – | – | -311.8% | |
| – | – | – | -30,129.4% | |
| – | – | – | -29,541.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 10 | 5 | 12 |
| Cash | 4 | 8 | 4 | 3 |
| Total debt | – | 0 | 0 | 0 |
| Total liabilities | 1 | 3 | 3 | 3 |
| 11 | 7 | 2 | 9 | |
| 0 | 0 | 0 | – | |
| -63.6% | -103.4% | -620.2% | -47.2% | |
| -79.8% | -129.1% | -799.8% | -58.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -6 | -7 | -13 | -4 | |
| 0 | 0 | 0 | 0 | |
| -6 | -7 | -13 | -4 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- 0.0×
- 161.1×
- –
- –
- -144.5%
- -183.4%
- 0.0%
Profitability
- -311.8%
- -30,129.4%
- -29,541.2%
- 0.0%
- -33.9%
- -216.9%
- -47.0%
- -26.7%
- -34.0%
- –
Growth
- –
- –
- +68.7%
- –
- +346.2%
Financial health
- -0.7×
- 0.00
- 0.2%
- –
- 1.78
- 1.78
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 952
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Oct 2, 2025 | -9.60 | – | – |
| Oct 1, 2025 | -9.60 | – | – |
| Jun 4, 2025 | -13.63 | – | – |
| Apr 4, 2025 | -83.98 | – | – |
| Nov 19, 2024 | -15.04 | -4.74 | −217.2% |
| Aug 15, 2024 | -9.60 | -6.24 | −53.8% |
| May 15, 2024 | -65.27 | -2.40 | −2,619.6% |
| Feb 29, 2024 | -83.98 | -1.49 | −5,536.2% |
News
Ocean Power Technologies plunges 42% after pricing $3M offeringSeeking Alpha · Nov 13, 2026ABAXX Technologies reports Q3 resultsSeeking Alpha · Nov 12, 2026Lumen Technologies (LUMN) Could Be 47% Undervalued On Fresh Third Quarter ResultsYahoo Finance · Nov 8, 2026bioAffinity Technologies GAAP EPS of -$5.89, revenue of $1.1MSeeking Alpha · Nov 6, 2026The Biggest Takeaway From Palantir Technologies’ Latest Quarterly Report Is a Potential Warning Sign Investors Shouldn’t MissYahoo Finance · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
68Pass
Philip Fisher
33No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
45No pass
Terry Smith
40No pass
Questions about PRF Technologies
Is PRF Technologies a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PRF Technologies AI analysis
What does PRF Technologies do?
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It is in Drug Manufacturers - Specialty & Generic.
Does PRF Technologies pay a dividend?
No. PRF Technologies does not pay a dividend at the moment.
Is PRF Technologies stock halal?
No. PRF Technologies does not pass our halal screen: its cash and confirmed interest-bearing investments are 114% of its market value, at or above the 33% limit. How we check
How has PRF Technologies stock done over the past year?
Down 83.2% over the past twelve months, to $0.78. It traded between $0.71 and $5.65 and is 86.1% below its high.
Who are PRF Technologies's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with PRF Technologies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.